MRNA · Full Picture

Moderna, Inc. — the full picture

Trailing window · 2026-05-11 to 2026-08-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 59
    quote_verified
    Moderna reported revenues of $145 million for the quarter and a GAAP loss of $1.97 per share.
  2. Guidance / Outlook · Guidance & outlookPriority 57
    1 forward row(s); quote_verified
    Moderna reiterated its target of up to 10% revenue growth for 2026.
  3. Litigation Settlement Exposure · Litigation & settlementsPriority 57
    quote_verified
    Roivant Sciences reported its liquidity was significantly bolstered by a $771.6 million litigation settlement receivable from Moderna, which was collected in July 2026.
  4. Product / Drug Pipeline Progress · Products & launchesPriority 37
    2 forward row(s); quote_verified
    The program is part of an expanded collaboration with CEPI, which has committed up to US$50 million to support its development.
  5. Regulatory Approval Milestones · Regulatory action & investigationsPriority 34
    1 forward row(s); quote_verified
    mFLUSIVA (mRNA-1010) has been approved by the U.S. Food and Drug Administration for use in all adults 50 years and older.
  6. Operating Expense Trends · Operating expenses (SG&A)Priority 32
    quote_verified
    A Form 144 SEC filing on August 5, 2026 indicates a proposed sale of 499,246 shares of common stock with an aggregate market value of $28,956,268.00 resulting from a stock option exercise by an individual with a relationship to the issuer.
  7. Litigation and Legal Risk · Litigation & settlementsPriority 31
    quote_verified
    Moderna has appealed a District Court judgment concerning patent infringement related to its COVID-19 vaccines, arguing that the U.S. government should bear the liability under 28 U.S.C. § 1498(a).

Threads by pillar

Revenue & Demand Priority 61 · 2 threads

Costs & Margins Priority 32 · 1 thread

Legal, Regulatory & Policy Priority 61 · 3 threads

Guidance & Outlook Priority 57 · 1 thread